Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Medicine > 2025 Vol. 3 > No. 3 > 100151
Next Article Previous Article
NEWS & BUZZ   Open Access     Cite

Nerandomilast shatters decade-long stalemate in fibrotic lung diseases: FDA fast track insights

  • 1.

    Department of Respiratory and Critical Care Medicine, Xiangya Hospital, Central South University, Changsha 410008, China

  • 2.

    The Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE, State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University, Chengdu 610041, China

  • 3.

    Department of Pulmonary and Critical Care Medicine, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu 610000, China

  • 4.

    School of Pharmacy, Queen’s University Belfast, Belfast BT7 1NN, UK

More Information
The Innovation Medicine  3(3),  https://doi.org/10.59717/j.xinn-med.2025.100151  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] Raghu G., Remy-Jardin M., Richeldi L., et al. (2022). Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An official ATS/ERS/JRS/ALAT clinical practice guideline. Am. J. Respir. Crit. Care Med. 205:e18−e47. DOI:10.1164/rccm.202202-0399ST

    View in Article CrossRef Google Scholar

    [2] Richeldi L., Azuma A., Cottin V., et al. (2025). Nerandomilast in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 392:2193−2202. DOI:10.1056/NEJMoa2414108

    View in Article CrossRef Google Scholar

    [3] Mo C., Li H., Yan M., et al. (2024). Dopaminylation of endothelial TPI1 suppresses ferroptotic angiocrine signals to promote lung regeneration over fibrosis. Cell Metab. 36:1839−1857.e1812. DOI:10.1016/j.cmet.2024.07.008

    View in Article CrossRef Google Scholar

    [4] Reininger D., Wolf F., Mayr C. H., et al. (2025). Insights into the cellular and molecular mechanisms behind the antifibrotic effects of nerandomilast. Am. J. Respir. Cell Mol. Biol. Online ahead of print DOI:10.1165/rcmb.2024-0614OC.

    View in Article Google Scholar

    [5] Maher T. M., Assassi S., Azuma A., et al. (2025). Nerandomilast in patients with progressive pulmonary fibrosis. N. Engl. J. Med. 392:2203−2214. DOI:10.1056/NEJMoa2503643

    View in Article CrossRef Google Scholar

    • Cited by

  • Cite this article:

    Zhou A., Lang Q., Zhao C., et al. (2025). Nerandomilast shatters decade-long stalemate in fibrotic lung diseases: FDA fast track insights. The Innovation Medicine 3:100151. https://doi.org/10.59717/j.xinn-med.2025.100151
    Zhou A., Lang Q., Zhao C., et al. (2025). Nerandomilast shatters decade-long stalemate in fibrotic lung diseases: FDA fast track insights. The Innovation Medicine 3:100151. https://doi.org/10.59717/j.xinn-med.2025.100151

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(4491) PDF downloads(10006)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Website copyright © Innovation Press. Published articles are licensed under CC BY with copyright retained by the authors.